title: Preprocedural hemoglobin predicts mortality following peripheral vascular interventions.
abstract: BACKGROUND
  Serum hemoglobin (H) level is a well-known predictor of all-cause mortality in patients undergoing percutaneous coronary interventions but has not been studied in patients undergoing peripheral vascular interventions (PVI). We sought to determine the prognostic significance of serum H in patients undergoing PVI.
  
  
  METHODS
  We identified 346 consecutive patients undergoing PVI who had a documented a baseline and a postprocedural serum H level over a 33-month period. A multivariate analysis of predictors of 9-month mortality was performed.
  
  
  RESULTS
  Of 346 patients identified, there were 28 deaths (8.1%) over a 9-month follow-up period. Periprocedural H change was not associated with death [OR: 1.12 (95% CI: 0.71-1.79), P = NS]. In a multivariate model independent predictors of all-cause mortality were clinical bleeding [OR: 10.7 (95% CI: 0.012-0.769), P = 0.026], emergency intervention [OR: 4.5 (95% CI: 0.07-0.71), P = 0.011], ejection fraction [OR: 1.02 (95% CI: 1.01-1.05), P = 0.020], and preprocedural H [OR: 1.56 (95% CI: 1.19-2.04) P = 0.001].
  
  
  CONCLUSIONS
  In patients undergoing PVI, preprocedural H was a significant predictor of 9-month all-cause mortality. The highest mortality rate was seen in patients with a preprocedural H level ≤ 10 g/dl. Preprocedural H level can be used in clinical practice to risk stratify patients being considered for PVI. Further investigation is needed to assess if optimization of H level preprocedure improves midterm mortality.
authors.affiliation: Department of Cardiology, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, Louisiana 70120, USA. zjaffery@ochsner.org
authors.forename: Zehra
authors.initials: Z
authors.lastname: Jaffery
authors.forename: Lior
authors.initials: L
authors.lastname: Shamai
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: White
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D015536:Down-Regulation; D057510:Endovascular Procedures / Q000009:adverse effects / Q000401:mortality*; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D016015:Logistic Models; D008145:Louisiana; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006454:Hemoglobins